이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

POINT Biopharma Global 대차 대조표 상태

재무 상태 기준 확인 6/6

POINT Biopharma Global 의 총 주주 지분은 $424.2M 이고 총 부채는 $0.0, 이는 부채 대 자기자본 비율을 0% 로 가져옵니다. 총자산과 총부채는 각각 $477.7M 및 $53.5M 입니다. POINT Biopharma Global 의 EBIT는 $107.8M 이며 이자보상배율은 -7.1 입니다. $339.2M 의 현금 및 단기 투자금을 보유하고 있습니다.

주요 정보

부채 비율

US$0

부채

이자 보상 비율	-7.1x
현금	US$339.16m
주식	US$424.19m
총 부채	US$53.51m
총 자산	US$477.70m

최근 재무 상태 업데이트

We Think POINT Biopharma Global (NASDAQ:PNT) Can Easily Afford To Drive Business Growth

Feb 01

Recent updates

POINT Biopharma Global Inc. (NASDAQ:PNT) Analysts Just Slashed This Year's Estimates

Aug 20

We Think POINT Biopharma Global (NASDAQ:PNT) Can Easily Afford To Drive Business Growth

Feb 01

재무 상태 분석

단기부채: PNT 의 단기 자산 ( $353.2M )이 단기 부채( $38.7M ).

장기 부채: PNT 의 단기 자산( $353.2M )이 장기 부채( $14.8M ).

부채 대 자본 내역 및 분석

부채 수준: PNT 부채가 없습니다.

부채 감소: PNT 5년 전에 부채가 없었습니다.

부채 범위: PNT 은 부채가 없으므로 영업현금흐름으로 충당할 필요가 없습니다.

이자 보장: PNT 에는 부채가 없으므로 이자 지불에 대한 보장은 문제가 되지 않습니다.

POINT Biopharma Global 대차 대조표 상태

재무 상태 기준 확인 6/6

주요 정보

최근 재무 상태 업데이트

POINT Biopharma Global Inc. Files Form 15

POINT Biopharma Global to be Delisted from the Nasdaq Capital Market Following the Consummation of the Merger

We Think POINT Biopharma Global (NASDAQ:PNT) Can Easily Afford To Drive Business Growth

Recent updates

POINT Biopharma Global Inc. Files Form 15

POINT Biopharma Global Inc.(NasdaqCM:PNT) dropped from S&P Biotechnology Select Industry Index

POINT Biopharma Global Inc.(NasdaqCM:PNT) dropped from NASDAQ Composite Index

Eli Lilly and Company (NYSE:LLY) completed the acquisition of POINT Biopharma Global Inc. (NasdaqCM:PNT) from Joe A. McCann, Allan Charles Silber, Neil E. Fleshner and others.

POINT Biopharma Global to be Delisted from the Nasdaq Capital Market Following the Consummation of the Merger

Price target decreased by 19% to US$13.85

Lantheus Holdings, Inc. and POINT Biopharma Global Inc. Announce Positive Topline Results from Pivotal Splash Trial in Metastatic Castration-Resistant Prostate Cancer

Consensus revenue estimates increase by 24%

Eli Lilly and Company (NYSE:LLY) entered into a definitive agreement to acquire POINT Biopharma Global Inc. (NasdaqCM:PNT) from Joe A. McCann, Allan Charles Silber, Neil E. Fleshner and others for approximately $1.4 billion.

New major risk - Share price stability

Price target decreased by 9.2% to US$15.44

Investor sentiment improves as stock rises 81%

Consensus revenue estimates fall by 54%

POINT Biopharma Global Inc. (NASDAQ:PNT) Analysts Just Slashed This Year's Estimates

High number of new directors

POINT Biopharma Global Inc. Expands Its Research with Next-Generation Isotopes, Publishing New Preclinical Data at SNMMI's Annual Congress

Point Biopharma Global Inc. Appoints Bridget Martell to Its Board of Directors

Consensus EPS estimates upgraded to US$0.80 loss

POINT Biopharma Announces FRONTIER Trial-in-Progress Poster Presentation at ASCO

Price target increased by 7.3% to US$16.90

Investor sentiment improves as stock rises 20%

Investor sentiment improves as stock rises 18%

Independent Director exercised options to buy US$122k worth of stock.

Forecast to breakeven in 2024

We Think POINT Biopharma Global (NASDAQ:PNT) Can Easily Afford To Drive Business Growth

Point Biopharma Completes Randomization in PNT2002’s Phase 3 Splash Trial

POINT Biopharma Global Inc. Releases New Preclinical Data Supporting the Combination of 177Lu-PNT6555 with Immunotherapy

Executive Chairman recently bought US$311k worth of stock

Forecast to breakeven in 2024

Forecast to breakeven in 2024

Price target decreased to US$19.00

High number of new directors

POINT Biopharma Publishes Preclinical Data for Actinium-Labelled PNT2001, A Next-Generation PSMA Ligand, At EANM's Annual Congress

A Look At The Fair Value Of POINT Biopharma Global Inc. (NASDAQ:PNT)

Point Biopharma plummets on announcing common stock offering

Price target increased to US$21.00

POINT Biopharma Global GAAP EPS of -$0.27 misses by $0.05

POINT Biopharma Announces Appointment of Chris Horvath as Executive Vice President, Commercial

Chief Medical Officer & Director recently sold US$4.2m worth of stock

POINT Biopharma Global Inc. Unveils FRONTIER: A Pan-Cancer Fap-A Targeted Clinical Program

POINT Biopharma Global Inc. Confirms No Supply Shortages of 177Lu-PNT2002 for the Splash Trial

High number of new and inexperienced directors

POINT Biopharma Global Announces First Patient in European Union (EU) Dosed in the Phase 3 Splash Trial

POINT Biopharma Announces Abstract Publication of Dosimetry Data Findings from the Lead-In Cohort of the SPLASH Trial in mCRPC at the 2022 SNMMI Mid-Winter & ACNM Annual Meeting

POINT Biopharma Global Inc., Annual General Meeting, Jun 02, 2022

High number of new and inexperienced directors

POINT Biopharma Global Inc. Releases New Data and Exercises Option for Best-In-Class FAP Inhibitor

POINT Biopharma Global Inc. Announces Initiation of Randomization for Its Phase 3 SPLASH study Evaluating PNT2002 for mCRPC

POINT Biopharma Announces Early Completion of Enrollment and Initial Dosing in the Lead-In of Its Phase 3 SPLASH Study of PNT2002 for mCRPC

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

건강한 기업 발견하기